Molecularly Tailored Therapy for Patients With Metastatic Cancer of the Esophagus and Stomach
| Status: | Terminated |
|---|---|
| Conditions: | Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 9/8/2018 |
| Start Date: | February 2015 |
| End Date: | November 2016 |
A Pilot Study of Molecular Profile-Directed Chemotherapy for Metastatic HER2(-) Esophagogastric Adenocarcinoma
The purpose of this study is to determine whether molecular profile-directed therapy
(otherwise known as personalized treatment) can improve the effectiveness of standard
chemotherapy combinations for patients with esophagogastric adenocarcinoma. A series of tests
will be performed on a sample of tumor; based on the results of these tests, a patient will
be assigned to a chemotherapy treatment.
(otherwise known as personalized treatment) can improve the effectiveness of standard
chemotherapy combinations for patients with esophagogastric adenocarcinoma. A series of tests
will be performed on a sample of tumor; based on the results of these tests, a patient will
be assigned to a chemotherapy treatment.
Inclusion Criteria:
- Advanced, measurable metastatic esophagogastric adenocarcinoma by RECIST criteria
- Patients who have had surgery or radiotherapy with or without neoadjuvant or adjuvant
chemotherapy (the wash-out period will be at least 1 month)
- Patients who are not eligible for resection and are chemotherapy naïve
- Patients with HER2(-) status
- Patients who have tumor deposit(s) that are easily accessible by ultrasound or CT
guidance
- Patients must have adequate organ function
- Patients must provide written informed consent
Exclusion Criteria:
- Active concurrent malignancy, other than superficial, non-squamous cell carcinoma of
the skin or uterine cervix, within the past three years
- ECOG performance status worse than 2
- Prior oral or intravenous chemotherapy for metastatic disease
- Patients with comorbidities that prevent them from being able to receive the
chemotherapy regimen
- cardiac ejection fraction 45% or greater
We found this trial at
1
site
3700 O St NW
Washington, District of Columbia 20057
Washington, District of Columbia 20057
(202) 687-0100
Principal Investigator: John Marshall, MD
Phone: 202-687-6974
Georgetown University Georgetown University is one of the world's leading academic and research institutions, offering...
Click here to add this to my saved trials
